Femasys Inc. has announced the commercial launch of FemaSeed Complete, a groundbreaking fertility solution that allows OB/GYNs to perform first-line insemination procedures directly within their practices. This development is particularly significant given that approximately 10 million women in the U.S. face infertility, yet less than half seek treatment, and only a small fraction undergo IVF. The launch addresses a critical gap in fertility care access, as fewer than 2,000 infertility specialists are available nationwide, leading to delays and barriers for patients seeking timely intervention.

The FemaSeed Complete system integrates FemaSeed intratubal insemination (ITI) with FemSperm, streamlining the workflow by eliminating the need for external lab processing or referrals. Clinical data indicates that FemaSeed achieves more than double the pregnancy rate of traditional intrauterine insemination (IUI) while maintaining a comparable safety profile. This innovation not only enhances patient satisfaction but also aligns with the increasing demand for cost-effective and accessible fertility treatments, particularly as U.S. fertility rates continue to decline.

The introduction of FemaSeed Complete signifies a paradigm shift in fertility care, enabling OB/GYNs to provide essential services that were previously limited to specialized clinics. This could accelerate research into in-office fertility treatments and reshape the landscape of reproductive health by fostering earlier interventions. As Femasys continues to expand its portfolio, including its FemBloc permanent birth control solution, the company is poised to significantly impact both clinical practices and patient outcomes in women’s reproductive health.

Source: globenewswire.com